Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Aster DM Healthcare now carries an updated analyst fair value estimate of ₹795.27, compared with the prior mark of ₹700.67, which represents about a 13.5% lift in the central valuation used in their models. Bullish and bearish commentators are split on how firmly this higher figure is backed by the new set of assumptions, especially around how sentiment reacts to future data points. As you read on, you will see how to track these shifting views and decide what they might mean for your own research on the stock.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Freedom Broker has recently initiated research coverage on Aster DM Healthcare, which adds another data point for you to cross check against the updated fair value estimate of ₹795.27.
-
The fresh coverage signals that Aster DM Healthcare is on the radar of institutional research desks, which some investors use as a reference when assessing how widely a stock is being followed and modeled.
🐻 Bearish Takeaways
-
With only limited disclosed Street research so far, including the single identified initiation from Freedom Broker, there is still a relatively small pool of published models for you to compare assumptions on valuation and execution risk.
-
The lack of a broad set of forecasts can make it harder to benchmark expectations around growth, margins, and capital allocation, so readers may wish to treat any one target or fair value input as just one piece of a still developing picture.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 1 risk for Aster DM Healthcare. See which could impact your investment.
What's in the News
-
Aster DM Healthcare has scheduled a board meeting on April 30, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
-
The Kerala nurse strike has been deferred by the Hon'ble High Court until May 31, 2026, with nursing staff back at work, operations reported at full capacity across affected Kerala hospitals, and an additional revenue loss of ₹57.76 million disclosed.
-
The company has detailed the earlier impact from the Kerala nurse strike that began on March 9, 2026, including operational disruption, a revenue loss of ₹176,874,860 from March 8 to March 13, 2026, contingency measures, and ongoing mediation ordered by the Hon'ble High Court.
-
Aster DM Healthcare plans to invest ₹960 million to expand the Women & Children facility at Aster Whitefield Hospital in Bengaluru. This expansion will increase total bed capacity from 380 to 539 and add specialized maternity and pediatric services.
How This Changes the Fair Value For Aster DM Healthcare
-
Fair value revised from ₹700.67 to ₹795.27, a change of about 13.5% in the central valuation mark.
-
Revenue growth assumption adjusted from 61.76% to 50.92% in the updated model.
-
Net profit margin assumption adjusted from 11.90% to 11.66% in the updated forecasts.
-
Future P/E multiple adjusted from 25.07x to 31.96x on projected earnings.
-
Discount rate adjusted from 12.48% to 12.51% in the latest valuation work.
Never Miss an Update: Follow The Narrative
Narratives link a company's story, its expansion plans, and its operating risks to a set of financial forecasts and a fair value anchor. They update automatically as new data, research, and news are added.
Head over to the Simply Wall St Community and follow the Narrative on Aster DM Healthcare to stay up to date on:
-
How the proposed merger with Quality Care India Ltd and planned bed additions across 38 hospitals in 27 cities could reshape Aster DM Healthcare's network and patient reach.
-
The role of higher value specialties, digital platforms, and operational efficiency programs in shaping revenue per bed, margins, and returns on capital.
-
Key execution risks around large capex projects, merger integration, reliance on price driven growth, and potential regulatory or cost pressures on profitability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASTERDM.nsei .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
